Clinical Trial

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 14, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is a multicenter, randomized, controlled phase Ш clinical study of comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with previous first-line treatment failure.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-04; most recent amendment 2024-11-12.
Status change: Enrolling by Invitation → Recruiting 2024-11-12
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-09-25
Trial Details
NCT Number NCT06296706
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Gastric Cancer
Enrollment 630 participants
Start Date 2024-02-27
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-14